Low Dose Naltrexone (LDN)

Naltrexone is an FDA-approved opioid receptor antagonist used at standard doses (50 mg) in the treatment of opioid and alcohol use disorders. At significantly lower doses -- typically 1.5 to 4.5 mg -- naltrexone is used off-label in a practice known as low dose naltrexone (LDN). At these sub-therapeutic doses, the pharmacological profile shifts in ways that have generated substantial clinical and research interest, particularly around immune modulation and inflammatory signaling.

The proposed mechanism of LDN centers on its brief, intermittent blockade of opioid receptors, which is thought to trigger a rebound upregulation of endogenous opioid activity. Additionally, LDN is hypothesized to act on microglial cells in the central nervous system -- the brain's resident immune cells -- in a way that may reduce neuroinflammatory signaling. These mechanisms are still being studied, and LDN's precise effects in humans across different conditions are an active area of research, with interest spanning autoimmune conditions, chronic pain, and general inflammatory burden.

LDN is typically taken orally once daily at bedtime, as the transient receptor blockade during overnight hours is thought to be central to its proposed mechanism. Compounded formulations allow for precise dosing at the low concentrations used in LDN protocols. Some individuals start at a lower dose and titrate upward with provider guidance. Common early side effects include vivid dreams and mild sleep disturbance, which typically resolve within a few weeks.

LDN may be a consideration for adults working with a provider on inflammatory health, autoimmune concerns, or longevity-focused protocols that include immune support. It is not appropriate for individuals currently taking opioid medications, including opioid pain medications or buprenorphine, as LDN will precipitate withdrawal. A thorough medication review is required before initiating.

This product is a compounded prescription and is dispensed only after a licensed provider reviews your health history and confirms there are no contraindications. It is not FDA-approved for longevity, autoimmune, or anti-inflammatory indications. Evidence supporting LDN is largely from smaller trials and observational data; larger randomized controlled trials are ongoing in several indications.